Clinical Trials
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
MM1OA-S03
A Randomized Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML: A myeloMATCH Substudy
Research Committee(s)
myeloMATCH
Leukemia
Activated
04-01-2025
ClinicalTrials.gov Registry Number
NCT06672146
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Status Notes
Initial Activation-Effective March 14, 2025, at 12:00 p.m. Pacific Time
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03-14-2025
ClinicalTrials.gov Registry Number
06498635
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2408
A Randomized Phase III Blinded Trial of lanreotide for the Prevention of Postoperative Pancreatic Fistula
Research Committee(s)
Palliative and End of Life Care Committee
Gastrointestinal Cancer
Activated
02-14-2025
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S1900J
A Phase II Study of Amivantamab SC (subcutaneous) in Participants Previously Treated with High MET-Amplification for Stage IV or Recurrent Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)
Status Notes
S1900J will open to accrual September 27, 2024, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
09-27-2024
ClinicalTrials.gov Registry Number
NCT06116682
Open
Phase
Accrual
4%
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Status Notes
S2312 active as of 9/3/2024.
Research Committee(s)
Genitourinary Cancer
Activated
09-03-2024
ClinicalTrials.gov Registry Number
06470243
Open
Phase
Accrual
15%
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Status Notes
S2308 will open to accrual 08/01/2024, effective 3:00 p.m. EST
Research Committee(s)
Lymphoma
Activated
08-01-2024
ClinicalTrials.gov Registry Number
06337318